Abstract Details

Title Bevacizumab Plus Re-irradiation Therapy vs. Bevacizumab Monotherapy in the Treatment of Recurrent Glioblastomas: A Systematic Review and Meta-analysis

Topic Neuro-oncology

Presentation(s) P10 - Poster Session 10 (8:00 AM-9:00 AM)

Poster/Presentation
Number 6-009

Objective

This study evaluates the efficacy of re-irradiation combined with bevacizumab compared to bevacizumab alone in treating recurrent glioblastoma.

Background Glioblastomas are the most aggressive primary brain tumors, characterized by high recurrence rates. Standard treatment involves maximal surgical resection, followed by chemotherapy and radiotherapy. Bevacizumab has emerged as a promising therapeutic agent when combined with re-irradiation for recurrent glioblastomas.

Design/Methods A comprehensive literature review was conducted using PubMed, Cochrane, Embase, and Clinicaltrials.gov from inception until January 2025. A random-effects model of meta-analysis was applied using the Mantel-Haenszel method to synthesize hazard ratios (HR) for dichotomous outcomes with 95% confidence intervals. The I² and χ² statistics were used to evaluate interstudy heterogeneity. All analyses were performed using R Studio.

Results This meta-analysis included four studies with a total of 390 patients (205 vs 185). We found significantly improved progression-free survival (HR 2.00, 95% CI: [1.64-2.45]), p < 0.0.1, I2=0%) and overall survival (HR 2.00, 95% CI: [1.45-2.77]), p < 0.0.1, I2=58%) in bevacizumab combined with re-irradiation compared to bevacizumab monotherapy.

Conclusions The combination of re-irradiation and bevacizumab provides better treatment benefits and disease control compared to bevacizumab alone in treating recurrent glioblastoma. Our findings are limited by a small sample size, and we suggest conducting more robust studies with larger samples to understand the full potential of these modalities.

Authors/Disclosures
Muhammad Moiz Javed, MD PRESENTER	Dr. Javed has nothing to disclose.
Beenish Sabir (Rawalpindi Medical University)	Miss Sabir has nothing to disclose.
Haris Mumtaz Malik, MBBS	Dr. Mumtaz Malik has nothing to disclose.
Abdullah Bin Kamran	Mr. Bin Kamran has nothing to disclose.
Amina Khan, MBBS	Dr. Khan has nothing to disclose.
Muhammad Nabeel Saddique, MBBS	Mr. Saddique has nothing to disclose.
Fatima Faraz	Dr. Faraz has nothing to disclose.
Hammad Javaid	Mr. Javaid has nothing to disclose.
Afifa Kulsoom, FCPS	Dr. Kulsoom has nothing to disclose.
Mashaal Raheman, Jr., MBBS	Dr. Raheman has nothing to disclose.
Amna Iqbal, MBBS	Dr. Iqbal has nothing to disclose.
Shafaq Saleem, MBBS	Dr. Saleem has nothing to disclose.
Aiman Amir, MBBS	Miss Amir has nothing to disclose.

��ɫ��

��ɫ��